Bli medlem
Bli medlem

Du är här


AbCellera: Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies

Agreement Further Supports Teva's Novel Biologics Development ProgramJERUSALEM and VANCOUVER, British Columbia, Feb. 02, 2016 (GLOBE NEWSWIRE) --
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and AbCellera
have entered into a collaborative research agreement whereby AbCellera will
apply its high-throughput single cell antibody platform for the discovery of
rare monoclonal antibodies.

"We are pleased to work with AbCellera utilizing this company's novel
biologics technology," said Michael Hayden, MD, PhD, President of Global R&D
and Chief Scientific Officer at Teva. "This agreement will be complementary
to our existing antibody discovery process with the potential to strengthen
Teva's capabilities in novel biologics discovery."

Under the terms of the agreement, AbCellera will receive an upfront payment,
research payments, and is eligible to receive undisclosed downstream
milestones associated with the development and approval of therapeutic

"These are tough problems that need new technologies to move them forward. Our
platform brings important advantages to enable the discovery of rare
antibodies with defined specificity and functional activity against difficult
membrane protein targets," said Dr. Carl Hansen, President and CEO of
AbCellera. "We look forward to a close collaboration with the team of
scientists at Teva, and are excited at the chance to help advance this
important program."

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) is a leading
global pharmaceutical company that delivers high-quality, patient-centric
healthcare solutions to millions of patients every day. Headquartered in
Israel, Teva is the world's largest generic medicines producer, leveraging
its portfolio of more than 1,000 molecules to produce a wide range of generic
products in nearly every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of the central
nervous system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of addressing
unmet patient needs by combining drug development capabilities with devices,
services and technologies. Teva's net revenues in 2014 amounted to $20.3
billion. For more information, visit

About AbCellera Biologics Inc.

AbCellera is a privately held company that has developed a high-throughput
platform for the rapid discovery of therapeutic antibodies directly from
natural immune cells. The company's proprietary single cell technology can be
applied across multiple species and provides flexible assay formats to
identify antibodies with defined properties at a throughput of millions of B
cells per run. In addition to internal programs, AbCellera provides
pharmaceutical and biotechnology partners with access to state-of-the-art
antibody discovery capabilities to advance and accelerate therapeutic
development. For more information, visit

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995:

This release
contains forward-looking statements, which are based on management's current
beliefs and expectations and involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize additional
pharmaceutical products; competition for our specialty products, especially
Copaxone® (including competition from orally-administered alternatives, as
well as from generic equivalents such as the recently launched Sandoz
product) and our ability to continue to migrate users to our 40 mg/mL version
and maintain patients on that version; our ability to identify and
successfully bid for suitable acquisition targets or licensing opportunities
(such as our pending acquisitions of Allergan's generic business and Rimsa),
or to consummate and integrate acquisitions; the possibility of material
fines, penalties and other sanctions and other adverse consequences arising
out of our ongoing FCPA investigations and related matters; our ability to
achieve expected results from the research and development efforts invested
in our pipeline of specialty and other products; our ability to reduce
operating expenses to the extent and during the timeframe intended by our
cost reduction program; the extent to which any manufacturing or quality
control problems damage our reputation for quality production and require
costly remediation; increased government scrutiny in both the U.S. and Europe
of our patent settlement agreements; our exposure to currency fluctuations
and restrictions as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the intellectual
property rights of our specialty medicines; the effects of reforms in
healthcare regulation and pharmaceutical pricing, reimbursement and coverage;
governmental investigations into sales and marketing practices, particularly
for our specialty pharmaceutical products; adverse effects of political or
economic instability, major hostilities or acts of terrorism on our
significant worldwide operations; interruptions in our supply chain or
problems with internal or third-party information technology systems that
adversely affect our complex manufacturing processes; significant disruptions
of our information technology systems or breaches of our data security;
competition for our generic products, both from other pharmaceutical
companies and as a result of increased governmental pricing pressures;
competition for our specialty pharmaceutical businesses from companies with
greater resources and capabilities; the impact of continuing consolidation of
our distributors and customers; decreased opportunities to obtain U.S. market
exclusivity for significant new generic products; potential liability in the
U.S., Europe and other markets for sales of generic products prior to a final
resolution of outstanding patent litigation; our potential exposure to
product liability claims that are not covered by insurance; any failure to
recruit or retain key personnel, or to attract additional executive and
managerial talent; any failures to comply with complex Medicare and Medicaid
reporting and payment obligations; significant impairment charges relating to
intangible assets, goodwill and property, plant and equipment; the effects of
increased leverage and our resulting reliance on access to the capital
markets; potentially significant increases in tax liabilities; the effect on
our overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our business;
variations in patent laws that may adversely affect our ability to
manufacture our products in the most efficient manner; environmental risks;
and other factors that are discussed in our Annual Report on Form 20-F for
the year ended December 31, 2014 and in our other filings with the U.S.
Securities and Exchange Commission.

| IR Contacts: Kevin C. Mannix United States (215) 591-8912 |
| Ran Meir United States (215) 591-3033 |
| Tomer Amitai Israel 972 (3) 926-7656 |
| PR Contacts: Iris Beck Codner Israel 972 (3) 926-7687 |
| Denise Bradley United States (215) 591-8974 |
| Nancy Leone United States (215) 284-0213 |
| AbCellera Contact: Kevin Heyries Canada (604) 827-4151 |


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AbCellera via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.